drugset / Trial / NCT05395507
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia
RandomizedParallel-groupOpen-labelTreatment
Summary
Objectives: To compare the efficacy and safety in Adult patients (≥18 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs. Interferon Alfa. Study Design: A prospective, open-label, multicenter, randomized controlled clinical trial.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2025-03-31
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 180 ug | — |
| Comparator | Recombinant Interferon Alpha | Protein / enzyme biologic | 300 unknown | — |